![Ioannis MANTZARIS | Fellowship | Albert Einstein College of Medicine, NY | AECOM | Albert Einstein Cancer Center | Research profile Ioannis MANTZARIS | Fellowship | Albert Einstein College of Medicine, NY | AECOM | Albert Einstein Cancer Center | Research profile](https://www.researchgate.net/publication/369258487/figure/tbl4/AS:11431281130772974@1679921037204/continued_Q320.jpg)
Ioannis MANTZARIS | Fellowship | Albert Einstein College of Medicine, NY | AECOM | Albert Einstein Cancer Center | Research profile
![1871865519 NPI Number | IOANNIS MANTZARIS M.D | BRONX, NY | NPI Registry | Medical Coding Library | www.HIPAASpace.com © 2023 1871865519 NPI Number | IOANNIS MANTZARIS M.D | BRONX, NY | NPI Registry | Medical Coding Library | www.HIPAASpace.com © 2023](https://www.hipaaspace.com/medical_billing/coding/national_provider_identifier/codes/npi_1871865519.png)
1871865519 NPI Number | IOANNIS MANTZARIS M.D | BRONX, NY | NPI Registry | Medical Coding Library | www.HIPAASpace.com © 2023
![PDF) Bevacizumab added to the irinotecan and capecitabine combination for advanced colorectal cancer: a well-tolerated, active and convenient regimen PDF) Bevacizumab added to the irinotecan and capecitabine combination for advanced colorectal cancer: a well-tolerated, active and convenient regimen](https://i1.rgstatic.net/publication/23495842_Bevacizumab_added_to_the_irinotecan_and_capecitabine_combination_for_advanced_colorectal_cancer_a_well-tolerated_active_and_convenient_regimen/links/09e41514873584ff13000000/largepreview.png)
PDF) Bevacizumab added to the irinotecan and capecitabine combination for advanced colorectal cancer: a well-tolerated, active and convenient regimen
![Ioannis MANTZARIS | Fellowship | Albert Einstein College of Medicine, NY | AECOM | Albert Einstein Cancer Center | Research profile Ioannis MANTZARIS | Fellowship | Albert Einstein College of Medicine, NY | AECOM | Albert Einstein Cancer Center | Research profile](https://www.researchgate.net/publication/369258487/figure/tbl2/AS:11431281130763308@1679921036975/continued_Q320.jpg)
Ioannis MANTZARIS | Fellowship | Albert Einstein College of Medicine, NY | AECOM | Albert Einstein Cancer Center | Research profile
![Less Is More: New Treatment Protocol for MDS and AML Is as Effective But Less Toxic than Standard Care | Newsroom | Albert Einstein College of Medicine Less Is More: New Treatment Protocol for MDS and AML Is as Effective But Less Toxic than Standard Care | Newsroom | Albert Einstein College of Medicine](https://www.einsteinmed.edu/images/dynamichomeimages/news/mendel-goldfinger-less-is-more-new-treatment-protocol-for-mds-and-aml.jpg)